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Pre-PCI Post-PCI P Value
Proximal Average
luminal diameter(ALD)
2.45  0.65 2.55  0.59 <0.05
Reference diameter 1.88  0.38 1.99  0.27 <0.05
Minimal lumen
diameter (MLD)
0.42  0.35 1.66  0.28 <0.0001
%Diameter
stenosis(DS)
77.0  19.1 16.5  11.1 <0.0001
Distal ALD 1.35  0.49 1.56  0.31 <0.0001
Total stented length 39.2  19.4
Acute gain 1.90  0.49
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Strut tissue coverage was classiﬁed according to published criteria (O-
SES vs. ZES, meanSD): Apposed uncovered struts, three-months: 6.14.4%
vs. 17.118.7% (n¼8 vs. n¼31, p¼0.631), six-months: 4.65.9% vs.
10.312.0% (n¼21 vs. n¼7, p¼0.068), nine-months: 1.51.8% vs. 6.58.9%
(n¼5 vs. n¼8, p¼0.190). Malapposed uncovered struts three-months: 6.212.8%
vs. 5.07.5% (p¼0.982), six-months: 4.35.6% vs. 3.34.5% (p¼ 0.629), nine-
months: 1.32.1% vs. 1.11.2% (p¼0.748). The intra-group analysis found no
statistical differences between the observed time-points. Neointimal thickness
was: three-months: 94.833.5 vs. 96.335.7 (p¼0.760), six-months: 102.929.0
vs. 92.234.6mm (p¼0.264), nine-months: 98.634.8 vs. 161.382.0mm
(p¼0.070). To discriminate mature and immature tissue coverage OCT based
grey scale signal intensity (GSI) analysis was assessed. We found no statistical
differences either for intra-group and the inter-group comparison. Concerning 12-
months follow-up patients no statistical differences were found for clinical
follow-up.
Conclusions: No statistical differences between O-SES and ZES concerning stent
struts coverage as well as GSI based quality assessments were found. The data show
generally comparable healing characteristics and neointimal formation of the O-SES
and ZES.
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Background: Percutaneous coronary interventions (PCI) to small-diameter vessels
remain an important challenge because of increased complications.
Methods: Between May 2011 and January 2012, 83 patients with very small
coronary vessels (reference vessel diameter < 2.25 mm) were submitted to PCI.
Biolimus-eluting stent (BES) was deployed at a low pressure with long inﬂation
time.
Results: Two cases of distal edge dissection were observed and one of them
needed additional stent implantation. There was no major adverse cardiac event
(MACE), including cardiac death, myocardial infarction (MI) and target lesion
revascularization (TLR) during the initial hospitalization. The angiographic data
is shown in table. Average luminal diameters(ALD) in distal segments mark-
edly increased from baseline to post procedure (1.350.49 mm vs. 1.560.31,
p< 0.0001). At 12-months follow-up, the rate of MACE and TLR was 11.1%
and 8.1%, respectively. Distal ALD in patients without TLR signiﬁcantly
increased from post procedure to follow-up (1.540.30 mm vs. 1.680.32 mm,
p< 0.01).Conclusions: BES implantation to very small coronary vessels achieved a high
clinical success. Vessel diameter distal to stent markedly increased immediately after
initial PCI and became larger at 1-year follow-up in case without TLR.B176 JACC Vol 64/11/Suppl B j September 13TCT-603
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Background: Fatigue fracture of coronary stents is a recurring problem that may lead
to an array of complications. It is important, both for stent design and selection, to
better understand this phenomenon. In this study, the fatigue resistance of three
coronary stent designs was qualitatively compared through means of ﬁnite element
analysis in a patient-speciﬁc setting.
Methods: Finite element computer simulations were used to virtually deploy and
realistically deform three stent designs within a human coronary artery. The three stent
models (Element, Boston Scientiﬁc; Multi-Link 8, Abbott Vascular; Biomatrix Flex,
Biosensors) were generated based on micro-computed tomography scans of device
samples. The vessel geometry and deformation was modeled based on biplane ﬂuo-
roscopy images of a human right coronary artery at diastole and systole. After device
deployment and recoil the fatigue safety of the stents was evaluated by imposing a
cyclic deformation to the vessel model. The risk of fatigue fracture of different stents
or fracture locations within a speciﬁc stent is assessed based on these computer
simulations, and relative comparisons between stents can be made. Predicted fracture
locations and relative fatigue resistances are put into perspective of fatigue fracture
data reported in literature.
Results: For the investigated patient, the Element was the stent with the highest
relative fatigue safety. Relative to the Element stent, the fatigue safety of the Multi-
Link 8 and Biomatrix Flex stent was 95% and 91%, respectively. Unlike the Element,
both the Multi-Link 8 and Biomatrix Flex showed regions of low fatigue safety in the
connectors between rings. These results are in close agreement with fatigue fracture
data reported in literature.
Conclusions: The proposed method for comparing the relative fatigue resistance of
coronary devices in a patient-speciﬁc setting can be used to optimize device design
and selection.
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Background: Early reports revealed that a novel abluminal groove-ﬁlled biode-
gradable polymer sirolimus-eluting stent (named target eluting technology) FIRE-
HAWK (MicroPort Medical, Shanghai, China) was safe and effective in 1-year
follow-up in a large cohort of patients from the TARGET clinical program. We aimed
to investigate the long-term clinical outcomes of this novel stent.
Methods: An objective performance criterion (OPC) study was required by the
China Food and Drug Administration for new drug-eluting stent. The primary
endpoint, target lesion failure (TLF), was deﬁned as the composite of cardiac
death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion
revascularization (iTLR) at 12 months. A patient-level pooled data derived from–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Novel Metallic DES
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMTARGET I RCT (n¼227), TARGET I long stent cohort (n¼50), and TARGET II
registry (n¼730) was prospectively collected and analyzed in 1007 patients with de
novo native coronary lesions. All patients were exclusively treated with FIRE-
HAWK stent and the follow-up visits are at 1-, 6-, 12-month, and annually up to
5 years.
Results: 992 (98.5%) patients completed 2-year clinical follow-up. Between 1 and
2 years, 62% of patients discontinued DAPT and there were only 7 newly
occurred TLF events including 3 cardiac death, 1 TV-MI and 3 iTLR (table).
Importantly, no deﬁnite/probable stent thrombosis (ST) was observed in this cohort
5 days after implantation of FIREHAWK stents. Lesion length >¼30mm was
an independent predictor of TLF at 2 years (HR [95%CI]: 2.44 [1.32, 4.53],
p< 0.01).Table. Clinical Outcomes through 2 Years
1 Year 2 Years
(n¼1003) (n¼992)
Death, % (n) 0.8 (8) 1.4 (14)
Cardiac Death, % (n) 0.5 (5) 0.8 (8)
Myocardial Infarction, % (n) 2.8 (28) 3.1 (31)
Q Wave MI, % (n) 0.1 (1) 0.4 (4)
Non Q Wave MI, % (n) 2.7 (27) 2.7 (27)
Target Vessel MI, % (n) 2.8 (28) 2.9 (29)
Ischemia-Driven TLR, % (n) 0.9 (9) 1.2 (12)
Any Revascularization, % (n) 2.9 (29) 4.1 (41)
TLF, % (n) 3.9 (39) 4.6 (46)
PoCE (All-Cause Death / All Myocardial Infarction / Any
Revascularization), % (n)
4.1 (41) 7.8 (77)
Deﬁnite/Probable ST, % (n) 0.1 (1) 0.1 (1)Conclusions: The sustained 2-year clinical data indicates that FIREHAWK stent
could enable safety and efﬁcacy by a novel target eluting technology in mild to
moderate risk patients. However, large scale randomized trials (TARGET EU and III)
are needed to further conﬁrm its clinical beneﬁts in treating most complex patients/
lesions.TCT-606
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Background: In this randomized controlled study (RCT) we compare the clinical
efﬁcacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience Prime
Everolimus Eluting Stent (Xience) at 2 years in the complete study population as well
as in the diabetic and small vessel subgroups, which are known to have a higher risk
for cardiac complications.
Methods: A total of N¼458 subjects (63.410.0SD 36-80 yrs) were enrolled in
the BIOFLOW-II study, registered at clinicaltrials.gov (NCT01356888). All sub-
jects were stratiﬁed for diabetes and then randomly assigned (2:1) to receive the
Orsiro or the Xience stent. Six patients were excluded from the intention to treat
population. The diabetic subgroup accounted for 28.3% N¼128 (Orsiro N¼84,
Xience N¼44) of all subjects. The small vessel cohort included all subjects with a
reference vessel diameter 2.75mm, accounting for 57.3% N¼259 (Orsiro N¼168,
Xience N¼91) of all subjects. Clinical follow up visits are performed at 1, 6, 12
months and annually for up to 5 years after the procedure. All angiographic im-
ages were analyzed by the core lab of R. Waksman, MD at MedStar HealthJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteResearch Institute, Washington DC, USA. All clinical events were adjudicated by
3 independent cardiologists (MD:s).
Results: All three study groups showed comparable populations in both randomi-
zation arms in terms of demographics, current risk factors, clinical history and lesion/
vessel characteristics. The clinical endpoint of Target Lesion Failure (TLF) for
Orsiro vs Xience at 12 month in the three analyzed populations were: All patients –
6.5% for the Orsiro vs 8.0% for the Xience (p 0.5832) Diabetic subgroup - 6.0%
for the Orsiro vs 4.5% for the Xience (p 0.7201) Small vessel subgroup – 7.4% for
the Orsiro vs 12.3% for the Xience (p 0.2065) No stent thrombosis (deﬁnitive,
probable or possible) occurred through 12 months. The clinical 2-year follow up data
is currently being analyzed. Results will be presented for the ﬁrst time during the
meeting.
Conclusions: In this RCT the clinical event rates of the Orsiro SES with a biode-
gradable polymer the clinical event rates were low and comparable to the Xience
Prime through 12 months in all three analyzed populations.
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Background: Bioresorbable polymer coatings are hoped to minimize persistent
inﬂammation associated with durable polymer usage as a drug carrier in drug-
eluting stents (DES). We examined the time course of para-strut inﬂammation (PI)
of 3 contemporary DES featuring abluminal bioresorbable polymer coating
(SYNERGYTM ¼SY) and durable polymer coating (XIENCE PRIME¼EES and
RESOLUTE INTEGRITY¼ZES) in the familial hypercholesterolemic swine (FHS)
model.
Methods: Stents (SE¼29, EES ¼29, ZES¼29 and OMEGA BMS¼29) were
implanted in 87 coronary arteries in 29 FHS. Para-strut inﬂammation (PI) was deﬁned
as contiguous regions of inﬂammation in contact with, or surrounding struts, and
extending into the neointima, media or adventitia and examined histologically at 30,
90 and 180 days.
Results: At 30 days, PI was higher in BMS compared to the 3 DES. By 90 days, PI
had markedly subsided in the BMS, but peaked in all 3 DES groups. At 180 days, PI
in the SY resolved to a minimal level comparable to BMS (p¼0.95), while the other 2
DES continued to show higher average PI scores than SY and BMS (EES vs. SY p<
0.0001 and ZES vs. SY p¼0.03).
Conclusions: In the setting of early atherosclerosis present in the FHS model at the
age used (12-25 months at implant), the peak PI in DES is delayed in comparison to
BMS and its resolution is slower. Polymer resorption and lower total mass of the
abluminally applied polymer coating in SY appear to accelerate the resolution of PI as
projected, adding to the evidence that FHS is capable of modeling clinically relevant
responses to endovascular interventions.TCT-608
A New Thin-Strut, Low-Dose, Sirolimus-Eluting Stent With Abluminal-Only
Biodegradable Polymeric Coating: Safety and Efﬁcacy Clinical Performance of
the Inspiron Stent in High-Risk Patients
Guy F.A. Prado JR1, Pedro Henrique Craveiro Melo1, Celso Takimura1,
Gustavo M. Alves1, Welingson V. Guimarães1, Jose Mariani JR1, Luiz J. Kajita1,
Carlos M. Campos1, Breno A. Falcão1, Marcus N. Gama1, Gilberto Marchiori1,
Antonio Esteves-Filho1, Pedro E. Horta1, Micheli Z. Galon1, Andre G. Spadaro1,
Silvio Zalc1, Paulo R. Soares1, Marco A. Perin1, Expedito Ribeiro1,
Roberto Kalil-Filho1, Pedro A. Lemos1
1Heart Institute - InCor, University of Sao Paulo Medical School, Sao Paulo, Brazilnts - Drug-eluting: Novel Metallic DES B177
